OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free CSLLY Stock Alerts $92.14 -0.26 (-0.28%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$92.14▼$92.9750-Day Range$86.82▼$94.2952-Week Range$71.51▼$105.11Volume42,122 shsAverage Volume45,247 shsMarket Capitalization$89.05 billionP/E RatioN/ADividend Yield1.18%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get CSL alerts: Email Address CSL MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth13.74%From $3.13 to $3.56 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.50 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for CSL.Read more about CSL's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently increased by 63.16%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldCSL pays a meaningful dividend of 1.18%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 30.62% next year. This indicates that CSL will be able to sustain or increase its dividend.Read more about CSL's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSLLY. Previous Next 1.1 News and Social Media Coverage News SentimentCSL has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CSL this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.03% of the stock of CSL is held by institutions.Read more about CSL's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CSL are expected to grow by 13.74% in the coming year, from $3.13 to $3.56 per share.Price to Earnings Growth RatioCSL has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCSL has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyGuard Against the Coming Financial UpheavalAmerica’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. About CSL Stock (OTCMKTS:CSLLY)CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesMay 4, 2024 | americanbankingnews.comCSL (OTCMKTS:CSLLY) Trading 0.2% Higher May 2, 2024 | markets.businessinsider.comCSL : Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza VaccinesMay 2, 2024 | prnewswire.comRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three SeasonsApril 28, 2024 | msn.comHere is the dividend forecast to 2028 for CSL sharesApril 25, 2024 | investorplace.comCSL Stock Earnings: Carlisle Companies Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 16, 2024 | msn.comHow much do you need to invest in CSL shares for $8,000 in annual dividends?April 12, 2024 | markets.businessinsider.comUBS Sticks to Their Buy Rating for CSL (CMXHF)April 9, 2024 | afr.comMacquarie brokers say CSL is heading to $500 per shareApril 5, 2024 | investorplace.comCSLR Stock Earnings: Complete Solaria Beats EPS, Misses Revenue for Q4 2023April 2, 2024 | fool.com.auOwn CSL shares? You're receiving a healthy dividend boost today!March 28, 2024 | finance.yahoo.comVafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patientsMarch 26, 2024 | afr.comBlood giant CSL works up $US1 billion-plus bond deal; banks mandatedMarch 11, 2024 | finance.yahoo.comCSL Ltd's Dividend AnalysisMarch 6, 2024 | prnewswire.comCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. SeasonFebruary 15, 2024 | markets.businessinsider.comWilsons downgrades CSL (CMXHF) to a HoldFebruary 13, 2024 | fool.com.auCSL shares tumble despite first-half earnings beatFebruary 13, 2024 | afr.comWhat we learnt from CSL, Challenger, Seek and Breville’s resultsFebruary 13, 2024 | finanznachrichten.deCSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³February 12, 2024 | fool.com.auCSL share price on watch amid 20% profit jumpFebruary 12, 2024 | marketwatch.comCSL Says 1H Profit Rises, Boosts Dividend -- UpdateFebruary 12, 2024 | afr.comCSL shrugs off trial setback to post double-digit earnings growthFebruary 12, 2024 | wsj.comCSL Profit Rises, Boosts DividendFebruary 12, 2024 | msn.comCSL Limited falls after Phase 3 setback for key trialFebruary 12, 2024 | msn.comAsian stocks move little in holiday-thinned trade; CSL drags on AustraliaSee More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/13/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio29.44 P/E Growth2.16Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.31 billion Price / Sales6.69 Cash Flow$3.13 per share Price / Cash Flow29.47 Book Value$18.48 per share Price / Book4.99Miscellaneous Outstanding Shares966,510,000Free FloatN/AMarket Cap$89.05 billion OptionableNot Optionable Beta0.74 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 58)MD, CEO & Executive Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 59)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 63)BS(Hons), J.D., Executive VP of Legal & General Counsel Comp: $1.1MChristina HickieSenior Manager of CommunicationsMs. Roanne ParryChief Human Resources OfficerDr. Karen Etchberger (Age 66)Executive Vice President of Quality & Business Services Comp: $1.03MMs. Jemimah BrennanHead of Communications - Asia PacificDr. Andrew D. Nash BSc (Hons) (Age 62)GAICD, Ph.D., Senior Vice President of Research Dr. William Mezzanotte M.D. (Age 65)M.P.H., Executive VP & Head of Research and Development Comp: $1.46MMore ExecutivesKey CompetitorsBristol-Myers SquibbNYSE:BMYGSKNYSE:GSKZoetisNYSE:ZTSVertex PharmaceuticalsNASDAQ:VRTXRegeneron PharmaceuticalsNASDAQ:REGNView All Competitors CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed in 2024? CSL's stock was trading at $97.17 at the beginning of 2024. Since then, CSLLY shares have decreased by 5.2% and is now trading at $92.14. View the best growth stocks for 2024 here. Are investors shorting CSL? CSL saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 9,300 shares, an increase of 63.2% from the April 15th total of 5,700 shares. Based on an average daily trading volume, of 109,600 shares, the days-to-cover ratio is currently 0.1 days. View CSL's Short Interest. Is CSL a good dividend stock? CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.18%. Read our dividend analysis for CSLLY. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CSLLY) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.